Puzo Michael J Acquires 1,811 Shares of Johnson & Johnson (NYSE:JNJ)

Puzo Michael J raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,141 shares of the company’s stock after purchasing an additional 1,811 shares during the period. Johnson & Johnson makes up about 3.3% of Puzo Michael J’s portfolio, making the stock its 11th largest holding. Puzo Michael J’s holdings in Johnson & Johnson were worth $11,657,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Steward Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $34,000. Jackson Wealth Management LLC increased its position in Johnson & Johnson by 1.7% during the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after purchasing an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC increased its position in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares in the last quarter. Finally, Strategic Asset Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $50,000. 67.84% of the stock is owned by institutional investors.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Hait sold 29,699 shares of the firm’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares in the company, valued at $14,729,724.88. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

A number of research firms recently issued reports on JNJ. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Raymond James upped their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Bank of America started coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Finally, The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $188.57.

Shares of JNJ traded up $1.63 during trading hours on Thursday, hitting $183.73. 291,377 shares of the stock were exchanged, compared to its average volume of 8,073,488. The firm has a market capitalization of $483.08 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 3.03 and a beta of 0.72. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a 50-day moving average of $174.69 and a 200-day moving average of $169.04. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.61 by $0.06. The business had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 37.03%. Johnson & Johnson’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.59 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.2 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.46%. Johnson & Johnson’s dividend payout ratio is currently 57.14%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More